The Schlieren-based company has been an integral part of Roche Pharmaceutical Research and Early Development since 2005 and is a pioneer in antibody engineering in cancer immunotherapy. Its antibody glycosylation technology increases immune-mediated killing of cancer cells and builds the basis for improved cancer medicines.

Award
  • Nominated in 2018

  • Winner in 2019